News

Treatment with Uplizna (inebilizumab-cdon) effectively prevented disease attacks and disability worsening for Asian people with neuromyelitis optica spectrum disorder (NMOSD) in the Phase 2/3 N-MOmentum clinical trial, a new analysis found. “In the Asian [patient] subgroup, the risk of NMOSD attacks was reduced with [Uplizna] versus placebo ……

A Phase 2 clinical trial is testing InnoCare Pharma’s experimental oral medication orelabrutinib in people with neuromyelitis optica spectrum disorder (NMOSD). The trial (NCT05284175), being conducted at the Peking Union Medical College Hospital, in Beijing, China, was cleared by the country’s regulatory agency last year. InnoCare…

AstraZeneca has announced filing a legal challenge to certain aspects of the U.S. Inflation Reduction Act (IRA), arguing that there may be unintended but harmful consequences for people living with rare diseases such as neuromyelitis optica spectrum disorder (NMOSD). It joins a number of other pharmaceutical companies…

Neuromyelitis optica spectrum disorder (NMOSD) is associated with a faster loss of white matter volume in the brain, but taking the corticosteroid prednisolone may help counter this effect, according to a small study in Japan. The brain’s white matter contains the long, wire-like projections, or fibers, that nerves use…

A history of smoking is associated with poorer recovery from disease relapses in people with neuromyelitis optica spectrum disorder (NMOSD), a study reports. Findings indicate that patients who smoke or are past smokers are more likely to have neurological lesions that persist months after the relapse, and that these…

Certain neurological symptoms of neuromyelitis optica spectrum disorder (NMOSD) occur at higher rates in patients who also have systemic lupus erythematosus (SLE), according to a recent review study. Features of NMOSD, including longitudinally extensive transverse myelitis — a type of spinal cord inflammation — and involvement of certain…

Nearly two in 10 neuromyelitis optica spectrum disorder (NMOSD) patients develop new asymptomatic brain and spinal cord lesions during the period of disease remission, but these do not appear to increase risk of relapse, according to a study in Argentina. Asymptomatic, or silent, lesions are those that can be…

Neuromyelitis optica spectrum disorder (NMOSD) patients have significantly poorer nutritional status than healthy people which is associated with worse quality of life, a study found. Longer disease duration; poor sleep quality; being a woman; and higher levels of anxiety, depression, or fatigue were found to be significantly associated with…

The presence of certain self-reactive antibodies called antinuclear antibodies (ANAs) in the blood is associated with worse disability and more severe relapses in people with neuromyelitis optica spectrum disorder (NMOSD), according to a study from China. “Our results suggest that ANA seems to be more associated with severe disease…

Long-term use of the approved therapy Soliris (eculizumab) safely and effectively prevents relapses in the real world in people with neuromyelitis optica spectrum disorder (NMOSD) and antibodies against the AQP4 protein. That’s according to two-year interim data from an observational study in Japan, where Soliris was approved in…